Vivus licenses PDE5 inhibitor from Tanabe

VVUS received worldwide rights, except in Japan, China and certain Pacific Rim countries, to Tanabe's TA-1790 oral PDE5 inhibitor to treat male and female sexual dysfunction. Tanabe (Osaka, Japan) rec...